Domain-specific Interactions Between the P185 and Epidermal Growth Factor Receptor Kinases Determine Differential Signaling Outcomes
Xiaolan Qian,Donald M. O’Rourke,Zhizhong Fei,Hongtao Zhang,Chih-Ching Kao,Mark I. Greene
DOI: https://doi.org/10.1074/jbc.274.2.574
1999-01-01
Abstract:We expressed the epidermal growth factor receptor (EGFR) along with mutant p185neu proteins containing the rat transmembrane point mutation. The work concerned the study of the contributions made by various p185neusubdomains to signaling induced by a heterodimeric ErbB complex. Co-expression of full-length EGFR and oncogenic p185neu receptors resulted in an increased EGF-induced phosphotyrosine content of p185neu, increased cell proliferation to limiting concentrations of EGF, and increases in both EGF-induced MAPK and phosphatidylinositol 3-kinase (PI 3-kinase) activation. Intracellular domain-deleted p185neu receptors (T691stop neu) were able to associate with full-length EGFR, but induced antagonistic effects on EGF-dependent EGF receptor down-regulation, cell proliferation, and activation of MAPK and PI 3-kinase pathways. Ectodomain-deleted p185neu proteins (TΔ5) were unable to physically associate with EGFR, and extracellular domain-deleted p185neu forms failed to augment activation of MAPK and PI 3-kinase in response to EGF. Association of EGFR with a carboxyl-terminally truncated p185neu mutant (TAPstop) form did not increase transforming efficiency and phosphotyrosine content of the TAPstop species, and proliferation of EGFR·TAPstop-co-expressing cells in response to EGF was similar to cells containing EGFR only. Thus, neither cooperative nor inhibitory effects were observed in cell lines co-expressing either TΔ5 or TAPstop mutant proteins. Unlike the formation of potent homodimer assemblies composed of oncogenic p185neu, the induction of signaling from p185neu·EGFR heteroreceptor assemblies requires the ectodomain for ligand-dependent physical association and intracellular domain contacts for efficient intermolecular kinase activation. We expressed the epidermal growth factor receptor (EGFR) along with mutant p185neu proteins containing the rat transmembrane point mutation. The work concerned the study of the contributions made by various p185neusubdomains to signaling induced by a heterodimeric ErbB complex. Co-expression of full-length EGFR and oncogenic p185neu receptors resulted in an increased EGF-induced phosphotyrosine content of p185neu, increased cell proliferation to limiting concentrations of EGF, and increases in both EGF-induced MAPK and phosphatidylinositol 3-kinase (PI 3-kinase) activation. Intracellular domain-deleted p185neu receptors (T691stop neu) were able to associate with full-length EGFR, but induced antagonistic effects on EGF-dependent EGF receptor down-regulation, cell proliferation, and activation of MAPK and PI 3-kinase pathways. Ectodomain-deleted p185neu proteins (TΔ5) were unable to physically associate with EGFR, and extracellular domain-deleted p185neu forms failed to augment activation of MAPK and PI 3-kinase in response to EGF. Association of EGFR with a carboxyl-terminally truncated p185neu mutant (TAPstop) form did not increase transforming efficiency and phosphotyrosine content of the TAPstop species, and proliferation of EGFR·TAPstop-co-expressing cells in response to EGF was similar to cells containing EGFR only. Thus, neither cooperative nor inhibitory effects were observed in cell lines co-expressing either TΔ5 or TAPstop mutant proteins. Unlike the formation of potent homodimer assemblies composed of oncogenic p185neu, the induction of signaling from p185neu·EGFR heteroreceptor assemblies requires the ectodomain for ligand-dependent physical association and intracellular domain contacts for efficient intermolecular kinase activation. The ErbB family includes four members of homologous receptor tyrosine kinases, the epidermal growth factor receptor (EGFR 1The abbreviations used are: EGFR, epidermal growth factor receptor; EGF, epidermal growth factor; PI 3-kinase, phosphatidylinositol 3-kinase; HA, hemagglutinin; PAGE, polyacrylamide gel electrophoresis; MAP, mitogen-activated protein; MAPK, MAP kinase; mAb, monoclonal antibody; aa, amino acid(s); DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; PBS, phosphate-buffered saline; MTT, 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide); ERK, extracellular signal-regulated kinase; BS3, bis(sulfosuccinimidyl) suberate. or ErbB-1) (1Ullrich A. Coussens L. Hayflick J.S. Dull T.J. Gray A. Tam A.W. Lee J. Yarden Y. Libermann T.A. Schlessinger J. Downward J. Mayes E.L.V. Whittle N. Waterfield M.D. Seeburg P.H. Nature. 1984; 309: 418-425Crossref PubMed Scopus (1996) Google Scholar), ErbB-2·p185neu (2Schechter A.L. Stern D.F. Vaidyanathan L. Decker S.J. Drebin J.A. Greene M.I. Weinberg R.I. Nature. 1984; 312: 513-516Crossref PubMed Scopus (941) Google Scholar, 3Yamamoto T. Ikawa S. Akiyama T. Semba K. Nomura N. Miyajima N. Saito T. Toyoshima K. Nature. 1986; 319: 230-234Crossref PubMed Scopus (1064) Google Scholar), ErbB-3 (4Kraus M.H. Issing W. Miki T. Popescu N.C. Aaronson S.A. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 9193-9197Crossref PubMed Scopus (673) Google Scholar), and ErbB-4 (5Plowman G.D. Culouscou J. Whitney G.S. Green J.M. Carlton G.W. Foy L. Neubauer M.G. Shonyab M. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 1746-1750Crossref PubMed Scopus (689) Google Scholar). ErbB family proteins are widely expressed in epithelial, mesenchymal, and neuronal tissues, and play important roles in normal growth and development (6Dougall W.C. Qian X. Peterson N.C. Miller M.J. Samanta A. Greene M.I. Oncogene. 1994; 9: 2109-2123PubMed Google Scholar, 7Lee K.F. Simon H. Chen H. Hung M.C. Hauser C. Nature. 1995; 378: 394-398Crossref PubMed Scopus (1100) Google Scholar, 8Gassmann M. Casagranda F. Orioli D. Simon H. Lai C. Klein R. Lemke G. Nature. 1995; 378: 390-394Crossref PubMed Scopus (951) Google Scholar, 9Threadgill D.W. Dlugose A.A. Hansen L.A. Tennenbaum T. Lichti U. Lee D. LaMantia C. Mourton T. Herrup K. Harris R.C. Barnard J.A. Yuspa S.H. Coffey R.J. Magnuson T. Science. 1995; 269: 230-234Crossref PubMed Scopus (1270) Google Scholar). Aberrant expression of these ErbB proteins is frequently observed in human malignancies (10O'Rourke D.M. Zhang X. Greene M.I. Proc. Assoc. Am. Physicians. 1997; 109: 209-219PubMed Google Scholar). The transmembrane mutation in rat p185neu (also termed Tneu) (12Weiner D.B. Liu J. Cohen J.A. Williams W.V. Greene M.I. Nature. 1989; 339: 230-231Crossref PubMed Scopus (358) Google Scholar) serves as a paradigm for receptor dimerization that leads to constitutive kinase activation contributing to oncogenic transformation (11Bargmann C.I. Hung M.-C. Weinberg R.A. Cell. 1986; 45: 649-657Abstract Full Text PDF PubMed Scopus (812) Google Scholar, 12Weiner D.B. Liu J. Cohen J.A. Williams W.V. Greene M.I. Nature. 1989; 339: 230-231Crossref PubMed Scopus (358) Google Scholar, 13Weiner D.B. Kokai Y. Wada T. Cohen J.A. Williams W.V. Greene M.I. Oncogene. 1989; 4: 1175-1183PubMed Google Scholar). Additional support for this mechanism has come from the identification of a naturally occurring activated EGFR oncoprotein (ΔEGFR or EGFRvIII) in human tumors, which forms constitutive dimers and confers increased tumorigenicity (14Moscatello D.K. Montgomery R.B. Sundareshan P. McDanel H. Wong M.Y. Wong A.J. Oncogene. 1996; 13: 85-96PubMed Google Scholar, 15O'Rourke D.M. Nute E.J.L. Davis J.G. Wu C. Lee A. Murali R. Zhang H.-T. Qian X. Kao C.-C. Greene M.I. Oncogene. 1998; 16: 1197-1207Crossref PubMed Scopus (48) Google Scholar). Gene amplification and overexpression of ErbB-2 have been observed in a high frequency of human adenocarcinomas, including those of the breast and ovary, and these features correlate with poor clinical prognosis (16Slamon D.J. Clark G.M. Wong S.G. Levin W.J. Ullrich A. Mcguire W.L. Science. 1987; 235: 177-182Crossref PubMed Scopus (10011) Google Scholar,17Slamon D.J. Godolphin W. Jones L.A. Holt J.A. Wong S.G. Kieth D.E. Levin W.J. Stuart S.G. Udove J. Ullrich A. Press M.F. Science. 1989; 244: 707-712Crossref PubMed Scopus (6289) Google Scholar). Experimental support for this model is provided by in vitro transformation assays using cell lines overexpressing either protooncogenic rat p185c-neu or human ErbB-2 at levels of 106 receptors/cell (18Di Fiore P.P. Pierce J.A. Fleming T.P. Hazan R. Ullrich A. King C.R. Schlessinger J. Aaronson S.A. Cell. 1987; 51: 1063-1070Abstract Full Text PDF PubMed Scopus (508) Google Scholar, 19Hudziak R.M. Schlessinger J. Ullrich A. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 7159-7163Crossref PubMed Scopus (552) Google Scholar). Biochemical and biophysical analysis of baculovirus-expressed p185neu proteins further support the notion of receptor oligomerization as a mechanism of kinase activation of normal holoreceptors (20LeVea C.M. Myers J.N. Dougall W.C. Qian X. Greene M.I. Receptor. 1993; 3: 293-309PubMed Google Scholar, 21Samanta A. LeVea C.M. Dougall W.C. Qian X. Greene M.I. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 1711-1715Crossref PubMed Scopus (90) Google Scholar). Heterodimeric interactions govern many signaling properties within the ErbB receptor family. Co-expression of EGFR and p185c-neu at modestly elevated levels (105/cell) (but not either receptor independently) results in synergistic transformation (22Kokai Y. Myers J.N. Wada T. Brown V.I. LeVea C.M. Davis J.G. Dobashi K. Greene M.I. Cell. 1989; 58: 287-292Abstract Full Text PDF PubMed Scopus (283) Google Scholar), due to increase of the ligand binding affinity and catalytic kinase activity (23Wada T. Qian X. Greene M. Cell. 1990; 61: 1339-1347Abstract Full Text PDF PubMed Scopus (335) Google Scholar, 24Qian X.L. Decker S.J. Greene M.I. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 1330-1334Crossref PubMed Scopus (71) Google Scholar). Heterodimerization of EGFR and ErbB-2 has also been observed in human breast tumor lines (25Goldman R. Benlevy R. Peles E. Yarden Y. Biochemistry. 1990; 29: 11024-11028Crossref PubMed Scopus (213) Google Scholar). Moreover, ligand treatment promotes the assembly of an activated p185c-neu·EGFR kinase complex in many cells (24Qian X.L. Decker S.J. Greene M.I. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 1330-1334Crossref PubMed Scopus (71) Google Scholar), resulting in novel distinct cellular signaling events (26Dougall W.C. Qian X. Miller M.J. Greene M.I. DNA Cell Biol. 1996; 15: 31-40Crossref PubMed Scopus (11) Google Scholar). Therefore, the receptor tyrosine kinase ensemble can be activated not only by homodimer formation, but also by heterodimeric associations. In this regard, endodomain interactions between p185neu and EGFR appear to influence functional signaling outcomes (27Qian X. Dougll W.C. Fei Z. Greene M.I. Oncogene. 1995; 10: 211-219PubMed Google Scholar). In response to EGF or Neu differentiating factor/heregulin (a ligand for ErbB-3 and ErbB-4) family ligands (28Peles E. Yarden Y. BioEssays. 1993; 15: 815-824Crossref PubMed Scopus (260) Google Scholar, 29Carraway III, K.L. Sliwkowski M.X. Akita R. Platko J.V. Guy P.M. Nuijens A.A. Diamonti J. Vandlen R.L. Cantley L.C. Cerione R.A. J. Biol. Chem. 1994; 269: 14303-14306Abstract Full Text PDF PubMed Google Scholar), EGFR and ErbB-2 both form heterodimers with ErbB-3 and ErbB-4 (30Riese D.J. van Raaij T.M. Plowman G.D. Andrews G.C. Stern D.F. Mol. Cell. Biol. 1995; 15: 5770-5776Crossref PubMed Scopus (347) Google Scholar, 31Cohen B.D. Green J.M. Foy L. Fell H.P. J. Biol. Chem. 1996; 271: 4813-4818Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar, 32Pinkas-Kramarski R. Soussan L. Waterman H. Levkowitz G. Alroy I. Lavi S. Seger R. Ratzkin B.J. Sela M. Yarden Y. EMBO J. 1996; 15: 2452-2467Crossref PubMed Scopus (701) Google Scholar, 33Zhang K. Sun J. Liu N. Wen D. Chang D. Thomason A. Yoshinaga S.K. J. Biol. Chem. 1996; 271: 3884-3890Abstract Full Text Full Text PDF PubMed Scopus (198) Google Scholar, 34Tzahar E. Waterman H. Chen X. Levkowitz G. Karunagaran D. Lavi S. Ratzkin B.J. Yarden Y. Mol. Cell. Biol. 1996; 16: 5276-5287Crossref PubMed Scopus (874) Google Scholar). Heterodimers between p185neu·ErbB-2 and ErbB-3 are associated with activated signaling and the transformed phenotype in primary human cancer cells (35Alimandi M. Romano A. Curia M.C. Muraro R. Fedi P. Aaronson S.A. Di F.P. Kraus M.H. Oncogene. 1995; 10: 1813-1821PubMed Google Scholar). Existence of an ErbB-3·ErbB-4 heterodimer has not been convincingly demonstrated to date. More recent data support the notion that p185neu·ErbB-2 is the preferred heterodimerization partner of all ErbB receptors and a mediator for divergent cellular signaling in many distinct cell types (34Tzahar E. Waterman H. Chen X. Levkowitz G. Karunagaran D. Lavi S. Ratzkin B.J. Yarden Y. Mol. Cell. Biol. 1996; 16: 5276-5287Crossref PubMed Scopus (874) Google Scholar, 36Grause-Porta D. Beerli R.R. Daly J.M. Hynes N. EMBO J. 1997; 16: 1647-1655Crossref PubMed Scopus (1309) Google Scholar). The structural basis for ErbB receptor heterodimerization has not been completely defined and crystallographic information on dimerized ErbB receptor kinases is currently unavailable. Previous work has revealed that ectodomain interactions are sufficient to stabilize dimer formation between p185neu and EGFR in fibroblasts and transformed cells (5Plowman G.D. Culouscou J. Whitney G.S. Green J.M. Carlton G.W. Foy L. Neubauer M.G. Shonyab M. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 1746-1750Crossref PubMed Scopus (689) Google Scholar, 37Qian X. Dougall W.C. Hellman M.E. Greene M.I. Oncogene. 1994; 9: 1507-1514PubMed Google Scholar, 38Drebin J.A. Stern D.F. Link V.C. Weinberg R.A. Greene M.I. Nature. 1984; 312: 545-548Crossref PubMed Scopus (113) Google Scholar), which is supported by observations showing that a partial deletion of the EGF receptor ectodomain still allow dimer formation and receptor activation (14Moscatello D.K. Montgomery R.B. Sundareshan P. McDanel H. Wong M.Y. Wong A.J. Oncogene. 1996; 13: 85-96PubMed Google Scholar,15O'Rourke D.M. Nute E.J.L. Davis J.G. Wu C. Lee A. Murali R. Zhang H.-T. Qian X. Kao C.-C. Greene M.I. Oncogene. 1998; 16: 1197-1207Crossref PubMed Scopus (48) Google Scholar). Although the transmembrane alone can stabilize the formation of p185neu homodimers, the relative contributions of the transmembrane region and the ectodomain have not been directly compared regarding the formation of signaling heterodimers. In this study, we have constructed various p185neu deletion mutants in order to specifically compare signaling events resulting from associations between EGF receptors and either p185neuectodomain- or endodomain-derived mutant receptors. We have co-expressed EGFR with low levels of p185neu proteins, or their mutant derivatives, to monitor p185neu-mediated enhancement of cell growth and transformation in vitro and in vivo, and to analyze the influence of EGF-induced heterodimeric receptor interactions on downstream signaling effectors. Signaling resulting from heterodimeric associations between full-length EGFR and mutant p185neu proteins has revealed the functional importance of p185neu subdomains in the induction of Ras/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI 3-kinase) pathways contributing to cell growth and transformation. As described previously (20LeVea C.M. Myers J.N. Dougall W.C. Qian X. Greene M.I. Receptor. 1993; 3: 293-309PubMed Google Scholar, 39Myers J.N. LeVea C.M. Smith J.E. Kallen R.G. Tung L. Greene M.I. Receptor. 1992; 2: 1-16PubMed Google Scholar, 40Decker S.J. Harris P. J. Biol. Chem. 1989; 264: 9204-9209Abstract Full Text PDF PubMed Google Scholar), monoclonal antibody 7.16.4, polyclonal antiserum α-Bacneu, and NCT are reactive with the ectodomain, intracellular domain, and carboxyl terminus of p185neu, respectively. mAb 225 reactive with the ectodomain of EGFR was obtained from Dr. John Mendelsohn (M. D. Anderson Cancer Center, Dallas, TX). A polyclonal rabbit antiserum specifically against the COOH terminus of EGFR (termed CT) was provided by Dr. Stuart Decker (40Decker S.J. Harris P. J. Biol. Chem. 1989; 264: 9204-9209Abstract Full Text PDF PubMed Google Scholar). The anti-phosphotyrosine monoclonal antibody, PY20, was obtained from Santa Cruz Biotechnology (Santa Cruz, CA.). All the deletion mutants were derived from the rat oncogenic p185neu cDNA containing a single point mutation (V664G) in the transmembrane region. The TAPstop mutant, containing a 122-aa truncation of the COOH terminus was prepared as described previously (41Mikami Y. Davis J.G. Dobashi K. Dougall W.C. Myers J.N. Brown V.I. Greene M.I. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 7335-7339Crossref PubMed Scopus (14) Google Scholar). A T691stop species was prepared by site-directed mutagenesis and substitution of a stop codon for Thr-691, resulting in a large cytoplasmic deletion (42O'Rourke D.M. Qian X. Zhang H.T. Davis J.G. Nute E. Meinkoth J. Greene M.I. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 3250-3255Crossref PubMed Scopus (58) Google Scholar, 43Pruss R.M. Herschman H.R. Proc. Natl. Acad. Sci. U. S. A. 1977; 74: 3918-3921Crossref PubMed Scopus (207) Google Scholar). The ectodomain-deleted mutant TΔ5 neu protein was described previously (27Qian X. Dougll W.C. Fei Z. Greene M.I. Oncogene. 1995; 10: 211-219PubMed Google Scholar). These cDNAs encoding for mutant p185neu forms were all cloned into the pSV2neor/DHFR vector as described (44Qian X. LeVea C.M. Freeman J.K. Dougall W.C. Greene M.T. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 1500-1504Crossref PubMed Scopus (141) Google Scholar) for expression in murine fibroblasts. These wild-type or mutant p185neu cDNAs were also subcloned into pcDNA3 vector for transient expression in COS7 cells. pSRαEGFR/hygr vector (44Qian X. LeVea C.M. Freeman J.K. Dougall W.C. Greene M.T. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 1500-1504Crossref PubMed Scopus (141) Google Scholar) was used for full-length EGFR expression. Ten micrograms of the p185neu constructs were transfected into NR6 cells, a mouse fibroblast cell line devoid of endogenous EGF receptors (43Pruss R.M. Herschman H.R. Proc. Natl. Acad. Sci. U. S. A. 1977; 74: 3918-3921Crossref PubMed Scopus (207) Google Scholar), or NE91 cells expressing human EGFR (37Qian X. Dougall W.C. Hellman M.E. Greene M.I. Oncogene. 1994; 9: 1507-1514PubMed Google Scholar) by calcium phosphate precipitation. After 2–3 weeks of selection with Geneticin (0.9 mg/ml), the established stable clones were screened and characterized. Gene amplification by methotrexate was used to increase the p185neu receptor level. Expression of p185neu and its derivatives in resultant subclones was examined by flow cytometric analysis following anti-p185neu mAb 7.16.4 staining. Surface expression of p185neu proteins was then estimated by comparing the mean channel fluorescent intensity with that of B104-1-1 cells, as the level of p185neu in B104-1-1 cells was previously determined by 125I-labeled anti-neu mAb binding assay (22Kokai Y. Myers J.N. Wada T. Brown V.I. LeVea C.M. Davis J.G. Dobashi K. Greene M.I. Cell. 1989; 58: 287-292Abstract Full Text PDF PubMed Scopus (283) Google Scholar). EGFR numbers in NE91 cells and mutant p185neu co-transfected cells were determined by Scatchard assays as described (37Qian X. Dougall W.C. Hellman M.E. Greene M.I. Oncogene. 1994; 9: 1507-1514PubMed Google Scholar). These transfected clones were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal bovine serum (FBS, HyClone) at 37 °C in a 5% CO2 atmosphere. Subconfluent cells in 10-cm dishes were washed and starved in cysteine-free DMEM for 1 h, and grown in low cysteine-containing 5% FBS-DMEM containing 55 μCi/ml [35S]cysteine (Amersham Pharmacia Biotech) for 16 h for metabolic labeling. Alternatively, the unlabeled cells were cultured overnight in 10-cm Petri dishes. After treatment with or without EGF, cells were washed twice with cold phosphate-buffered saline (PBS) and treated with PBS containing 2 mmmembrane-impermeable cross-linker bis(sulfosuccinimidyl) suberate (BS3, Pierce), for 30 min. After quenching the cross-linking reaction with a buffer containing 10 mmTris-HCl (pH 7.6), 0.9% NaCl, and 0.1 m glycine, cells were washed twice with cold PBS and solubilized with PI/RIPA buffer as described (24Qian X.L. Decker S.J. Greene M.I. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 1330-1334Crossref PubMed Scopus (71) Google Scholar). The immunocomplexes were washed and solubilized, then separated by gradient SDS-PAGE gels (4–7.5%). Proteins from metabolically labeled cells were analyzed by autoradiography. Proteins from unlabeled cells were transferred onto nitrocellulose and then immunoblotted with anti-phosphotyrosine mAb PY20, anti-EGFR CT, or anti-p185 antiserum as indicated in the figures. The protein signals were identified by the binding of 125I-labeled protein A (NEN Life Science Products), or by enhanced chemiluminase (ECL) using ECL kit from Amersham Pharmacia Biotech. Cells (1 × 105) were plated in a six-well dish with DMEM containing 5% FBS overnight. Cells were then treated with EGF (50 ng/ml) for 0–4 h and were harvested and washed with cold PBS containing 0.5% bovine serum albumin and 0.1% sodium azide. Cell preparations were then incubated with a saturating amount (0.5 μg/reaction) of anti-neu mAb 7.16.4 or anti-EGFR mAb 225, or an irrelevant mAB (such as 9BG5 against the hemagglutinin of reovirus receptor), at 4 °C for 30 min, restained with fluorescein isothiocyanate-conjugated anti-mouse IgG (Sigma) for another 30 min after extensive washing. Cells were then fixed with 2% paraformaldehyde and analyzed by flow cytometry (FACScan, Becton Dickinson), as described previously (37Qian X. Dougall W.C. Hellman M.E. Greene M.I. Oncogene. 1994; 9: 1507-1514PubMed Google Scholar). Briefly, after subtracting the nonspecific background staining with 9BG5, the mean channel values from each time point were used to determine the percentage of surface expression of EGFR or p185neu proteins at the various time points after EGF treatment. Anchorage-independent growth ability was determined by assessing the colony forming efficiency of cells suspended in soft agar (15O'Rourke D.M. Nute E.J.L. Davis J.G. Wu C. Lee A. Murali R. Zhang H.-T. Qian X. Kao C.-C. Greene M.I. Oncogene. 1998; 16: 1197-1207Crossref PubMed Scopus (48) Google Scholar, 37Qian X. Dougall W.C. Hellman M.E. Greene M.I. Oncogene. 1994; 9: 1507-1514PubMed Google Scholar). Cells (1000/dish) were suspended in 7% FBS-DMEM containing 0.18% agarose, and plated on 0.25% basal agar in each dish. Cells were fed with DMEM supplemented with 7% FBS-DMEM, 20 mmHEPES (pH 7.5). Colonies (>0.3 mm) were visualized at day 21 for all cell lines after stained with p-iodonitrotetrazolium violet (1 mg/ml). Each cell line was examined in triplicate samples for separate experiments. To analyze the tumor growth in athymic mice, cells (1 × 106) of each line were suspended in 0.1 ml of PBS and injected intradermally in the mid-dorsum of NCR nude mice. PBS alone was also injected as a control. Animals used in this study were maintained in accordance with the guidelines of the Committee on Animals of the University of Pennsylvania and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resource. Tumor growth was monitored twice a week up to 10 weeks. Tumor size was calculated by this formula: 3.14/6 × (length × width × thickness) as described (27Qian X. Dougll W.C. Fei Z. Greene M.I. Oncogene. 1995; 10: 211-219PubMed Google Scholar). The 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) (MTT) assay for measuring cell growth has been described previously (38Drebin J.A. Stern D.F. Link V.C. Weinberg R.A. Greene M.I. Nature. 1984; 312: 545-548Crossref PubMed Scopus (113) Google Scholar). Briefly, cells (3000/well) of each cell line were seeded in 96-well plates overnight in DMEM containing 5% FBS. Cells were starved in serum-free ITS-DMEM for 48 h, then cultured in 100 μl of the same medium plus various concentrations of EGF for another 48 h. 25 μl of MTT solution (5 μg/ml in PBS) were added to each well, and after 2 h of incubation at 37 °C, 100 μl of the extraction buffer (20% w/v SDS, 50% N,N-dimethyl formamide, pH 4.7) was added. After an overnight incubation at 37 °C, the optical density at 600 nm was measured using an enzyme-linked immunosorbent assay reader. Each value represents a mean of four samples. COS7 cells were transiently transfected with pcDNA3-HA-ERK2 (a gift from Silvio Gutkind, National Institutes of Health, Bethesda, MD) and pSRαEGFR/hygr, along with either empty vector or plasmids expressing wild-type or mutant p185c-neu using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's instructions and assayed 48 h after transfection. Cells deprived of serum for 16–20 h were treated with or without EGF (50 ng/ml) for 5 min. For MAP kinase assay, cells were lysed with RIPA buffer (25 mmTris-HCl (pH 7.5), 0.3 m NaCl, 1.5 mmMgCl2, 1 mm MgCl2, 0.2 mm EDTA, 0.5 mm dithiothreitol, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 20 mmβ-glycerophosphate, 1 mm sodium orthovanadate, 10 μg/ml aprotinin, 1 mm phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin). Protein concentrations were determined by the BCA kit (Pierce). Equal amounts of protein (100 μg) from cell extracts were immunoprecipitated with anti-HA (BabCo). After washing extensively, the immunocomplexes were then incubated with 50 μl of reaction buffer (30 mm HEPES (pH 7.4), 10 mm MaCl2, 1 mm dithiothreitol, 5 μm ATP) containing 1 μCi of [γ-32P]ATP (NEN Life Science Products) and 2 μg of myelin basic protein (Upstate Biotechnology Inc.). After incubation for 20 min at 30 °C, kinase reactions were terminated by the addition of 2× Laemmli sample buffer. The samples were then resolved by SDS-PAGE, and the phosphorylated myelin basic protein was visualized by autoradiography. PI 3-kinase immune complex assays were carried out as described (45Moscatello D.K. Holgado-Madrugal M. Emlet D.R. Montgomery R.B. Wong A.J. J. Biol. Chem. 1998; 273: 200-206Abstract Full Text Full Text PDF PubMed Scopus (285) Google Scholar) with slight modifications. Cells were lysed in Nonidet P-40 lysis buffer (20 mm Tris-HCl (pH 7.4), 137 mm NaCl, 1 mm MgCl2, 1 mm CaCl2, 10% glycerol, 1% Nonidet P-40, 1 mm sodium orthovanadate, 10 μg/ml aprotinin, 1 mm phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin). Equal amounts of protein (600 μg) from cell extracts were immunoprecipitated with anti-phosphotyrosine 4G10 (Upstate Biotechnology Inc.) for 3 h. Protein A-Sepharose was then added and rotated at 4 °C for overnight. Immunocomplexes were washed twice with lysis buffer; twice with 100 mm Tris (pH 7.4), 0.5 m LiCl, 0.2 mm sodium orthovanadate, plus 0.2 mm adenosine; and twice with reaction buffer (10 mm HEPES (pH 7.5), 5 mm EDTA, 150 mm NaCl). The beads were resuspended in 40 μl of reaction buffer containing substrate mixture (phosphatidylinositol, phosphatidylinositol 4-phosphate, and phosphatidylserine dispersed by sonication in 10 mm HEPES (pH 7.5), 1 mm EGTA). The tubes were incubated at room temperature for 10 min and reaction were initiated by adding 5 μCi of [γ-32P]ATP (NEN Life Science Products) per reaction in 5 μl of 500 mm ATP and terminated by addition of 80 μl of CHCl3:CH3OH (1:1) after another 10 min. Phospholipids were extracted, desiccated, and redissolved as described (45Moscatello D.K. Holgado-Madrugal M. Emlet D.R. Montgomery R.B. Wong A.J. J. Biol. Chem. 1998; 273: 200-206Abstract Full Text Full Text PDF PubMed Scopus (285) Google Scholar). The samples were the chromatographed on thin layer chromatography plates (precoated with potassium oxalate and baked at 100 °C for 1 h before use) in CHCl3:CHOH:2.5 mNH4OH:H2O (45:35:2.7:7.3). Spots corresponding to phosphatidylinositol 3-phosphate and phosphatidylinositol 3,4-bisphosphate were visualized after autoradiography. Unlabeled phospholipid standards were included and were visualized by exposure to iodine vapor. Cell lines expressing EGFR and various p185neu deletion mutant proteins derived from full-length transforming p185neu were all generated in the NR6 cell background (43Pruss R.M. Herschman H.R. Proc. Natl. Acad. Sci. U. S. A. 1977; 74: 3918-3921Crossref PubMed Scopus (207) Google Scholar). In addition, stable transfectants derived from NR6 fibroblasts expressing human EGFR (termed NE91 cells) were also generated. NE91 cells, as well as NR6 parental cells, were then transfected with various p185neu cDNA constructs to express one of the following mutant p185neu proteins with or without EGFR, respectively (Fig. 1): (a) Er/p185neu or p185neu (full-length oncogenic p185neu product), (b) Er/T691stop or T691stop (lacking 591 aa from the carboxyl terminus), (c) Er/TAPstop or TAPstop (a 122-aa truncation at carboxyl terminus), and (d) Er/TΔ5 or TΔ5 (an ectodomain deleted p185neu product, also termed TΔ5). A schematic representation of the oncogenic p185neu protein and its mutant derivative species is shown in Fig. 1. B104-1-1 murine fibroblasts transformed by the expression of oncogenic p185neu were used as a positive control, since surface expression of p185neu, biochemical features of p185neu homodimerization and p185neu transforming potency have been characterized previously (13Weiner D.B. Kokai Y. Wada T. Cohen J.A. Williams W.V. Greene M.I. Oncogene. 1989; 4: 1175-1183PubMed Google Scholar, 22Kokai Y. Myers J.N. Wada T. Brown V.I. LeVea C.M. Davis J.G. Dobashi K. Greene M.I. Cell. 1989; 58: 287-292Abstract Full Text PDF PubMed Scopus (283) Google Scholar, 27Qian X. Dougll W.C. Fei Z. Greene M.I. Oncogene. 1995; 10: 211-219PubMed Google Scholar). As shown in TableI, relative expression levels of various p185neu mutant proteins in selected clones were estimated by a comparison with B104-1-1 cells, while the expression of EGFR in these cells was estimated by Scatchard analysis. In order to observe an enhancement of EGFR-mediated cellular signaling and transformation, clone Er/p185neu expressing